Author

B. McConeghy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:differential expression· 3 Research Focus:gene regulatory network inference· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Assay:whole-exome sequencing· 2

Frequent Co-Authors

S. Le Bihan· 4 shared A. Haegert· 3 shared R. H. Bell· 3 shared R. Shrestha· 3 shared S. Anderson· 3 shared S. Brahmbhatt· 3 shared S. Volik· 3 shared A. Churg· 2 shared

Activity by Year

2018-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

S. Le Bihan

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Functional mapping of androgen receptor enhancer activity

C.-C. F. Huang, S. Lingadahalli, T. Morova, D. Ozturan, E. Hu, I. P. L. Yu, S. Linder, M. Hoogstraat, S. Stelloo, F. Sar, H. van der Poel, U. B. Altintas, M. Saffarzadeh, S. Le Bihan, B. McConeghy, , N. A. Lack

The paper functionally maps AR enhancer activity using STARRseq, finding most AR binding sites are inactive or constitutively active, with inducible enhancers forming regulatory hubs that drive gene transcription.

bioRxiv · Aug 18, 2020Cancer Biology

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian Carcinoma

R. Shrestha, M. L. Fernandez, A. Dawson, J. Hoenisch, S. Volik, Y.-Y. Lin, S. Anderson, H. Kim, A. Haegert, S. Colborne, B. McConeghy, R. H. Bell, S. Brahmbhatt, G. E. DiMattia, S. Le Bihan, , M. S. Carey

This study uses multiomics analysis of LGSOC cell lines to identify therapeutic vulnerabilities and biomarkers for MEK inhibitor efficacy.

bioRxiv · Jun 18, 2020 · PreprintCancer Biology

Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma

R. Shrestha, N. Nabavi, S. Volik, S. Anderson, A. Haegert, B. McConeghy, S. Brahmbhatt, R. H. Bell, S. Le Bihan, Y. Wang, C. C. C. Collins, A. Churg

This study identifies distinct genetic mutations in well-differentiated papillary mesothelioma (WDPM) that differentiate it from malignant mesothelioma.

bioRxiv · Jul 23, 2019Cancer Biology

BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma

R. Shrestha, N. Nabavi, Y.-Y. Lin, F. Mo, S. Anderson, S. Volik, H. H. Adomat, D. Lin, H. Xue, X. Dong, R. Shukin, R. H. Bell, B. McConeghy, A. Haegert, S. Brahmbhatt, , C. C. Collins

The paper identifies BAP1 loss as a marker for a distinct immunogenic PeM subtype, suggesting potential therapeutic targets like immune checkpoint inhibitors.

bioRxiv · Dec 13, 2018Cancer Biology